Q BioMed CEO Talks About Partnership with Mannin Research

Q BioMed (OTCMKTS:QBIO) CEO Denis Corin and George Nikopoulos, PhD, MBA, CEO and president of Mannin Research were interviewed about the partnership between Mannin Research and Q BioMed on the feasibility of GDF-15, a biomarker for monitoring glaucoma.

As quoted in the interview:

PCON: How did the partnership with Washington University come about?

Nikopoulos: Q BioMed and Mannin have been working to develop a small molecule, as it is an unmet need for new treatments in patients with glaucoma. In our evaluation of the industry, we wanted to make sure we were meeting the needs of patients and physicians. One of the challenges has been determining how to find patients who have glaucoma and looking at them over time for progression of glaucoma. We were looking for partnerships with companies that had biomarkers applicable to glaucoma and were lucky to meet Dr. Apte’s group through the University of Washington’s Technology Transfer office. They were able to explain how her discoveries can be applied to physician and patient needs in glaucoma relating to detection and progression.

Corin: Right now, we are evaluating the technology from a Q BioMed standpoint. All of our partnerships, collaborations and licenses are built around evaluating a technology, testing the commercial viability and moving to the next stage of building that collaboration with the potential partner around a commercial asset. It’s not just all research and development; there has to be a business proposition behind it and a reason behind entering into a more substantial agreement. We have an option to license the technology after it’s been evaluated. We are in that process right now. When we are more comfortable that it has commercial viability and provides value to us and our platform and the ophthalmology vertical within Q BioMed, then we would move into a full licensing deal with Washington University. We’ve already sort of mapped out what those terms would look like. Then, the collaboration would be more formalized, and our teams would work even more closely together to lay out the commercial and clinical plan to make it into a viable commercial product.

For the full interview, click here.

Click here to connect with Q BioMed (OTCMKTS:QBIO)
for an Investor Presentation